Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Cue Biopharma, Inc. (CUE)

As of 2026-11-21 · 12/15 boxes filled from SEC filings and market data

Report price $4.15 (close 2026-11-20)

Conclusion: PASS

Conviction low · base case none · downside -79% · upside 0%

At $4.15, Cue Biopharma is priced below its $57.9M of net cash, with a $34.7M market cap, while TTM EBIT is -$138.2M and TTM free cash flow is -$51.2M; the market is therefore assigning little or no positive value to the operating business and is treating the revenue base as non-recurring. The call is PASS because no normalized earnings base exists and the priced cases offer no compensating base case. The downside is -78.8% to $0.88, on -75.0% book value at a compressed P/B of 0.77x (today 0.9x). There is no base case, because no independent peer median or own-history multiple was available and a base at today's multiple would be today's price by construction. The upside is 0.0% to $4.15, the analyst's own upside, with no earnings change given to price it. That leaves the priced asymmetry without a base anchor.

Key numbers

  • Share price: $4.15
  • Market cap: $34.7M
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $35.6M
  • FCF yield: -147.7%
  • Price / book: 0.90x
  • Earnings-quality flags (TTM): none flagged
  • Revenue growth (latest fiscal year): +195.7%

The 15 boxes

  1. ✓ 1. Long-form business notes

    Cue Biopharma (which filed earlier as Imagen Biopharma, Inc. until 2015-06-19) is a clinical-stage biopharmaceutical company with no product revenue: its revenue line — $3.2M FY2020, $14.9M FY2021, $1.2M FY2022, $5.5M FY2023, $9.3M FY2024, $27.5M FY2025, $35.6M TTM to Sep 2026 — is collaboration, license and option consideration, so the cycle is deal-driven, not demand-driven. Operating income was negative in every year of the six-year span, from -$26.6M (FY2025, the smallest loss) to -$53.2M (FY2022), and the TTM to Sep 2026 shows a -$138.2M operating loss and a -$206.7M net loss. Between the oldest and newest annual report the story moved from an internal oncology lead (CUE-101, in Phase 1 trials in FY2020) to out-licensed oncology (ImmunoScape, November 2025) and a preclinical autoimmune lead (CUE-401), with partner cash — $9.5M from ImmunoScape received in Q4 2025 — now the visible driver inside the $27.5M FY2025 revenue figure.

  2. ✓ 2. Competitive advantage

    Cue Biopharma has no durable, demonstrated advantage: it has never recorded product revenue, has a $368.5M accumulated deficit at FY2025 and cash of $27.1M, and its differentiation claim (Immuno-STAT, a masked TGF-b/IL-2) rests on company belief rather than on margin, price or efficacy evidence. Its only external validation is licensing — BI (April 2025, CUE-501) and IMSCP (November 2025, CUE-100 series) — deals that hand over exclusivity and, in BI's case, bar the company from B cell depletion during the research term. The record shows licensing income that swings year to year ($1.2M FY2022 to $27.5M FY2025) against negative operating income in every year FY2020-FY2025, so there is no operating leverage to point to.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $0.1 million versus $2.1 million in Q3 2025 because less BI collaboration work was recognized, while the nine months to Sep 2026 rose to $13.7 million from $5.5 million on a $7.5 million BI preclinical milestone and more BI activity. The quarter's $50.0 million net loss and $47.1 million operating loss are dominated by non-cash stock compensation from RSUs granted July 2026 (G&A $29.8M, R&D $17.0M) plus a $3.4 million non-cash warrant-related revaluation loss, not by any change in commercial activity; the company has never booked product revenue. Cash of $57.9 million at Sep 30 2026 is stated to fund at least the next twelve months, after roughly $28 million of one-time Ascendant license outflows in the nine months. No numeric revenue or earnings guidance is given in either the 10-Q or the same-quarter release, and the risk factors repeat the need for substantial additional capital and dilution.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans